Print this page    •   Back to Web version of article

Telaprevir Under Study for HIV/HCV Coinfection

By Liz Highleyman

Winter/Spring 2010

The investigational hepatitis C virus (HCV) protease inhibitor telaprevir -- the furthest along of the new directly targeted antiviral agents -- is now being tested in HIV/HCV coinfected individuals. The drug has demonstrated good antiviral activity in combination with pegylated interferon plus ribavirin in clinical trials of people with hepatitis C alone, and developer Vertex Pharmaceuticals plans to request FDA approval in the second half of this year. For further information, see "Open Clinical Trials."

Liz Highleyman (liz@black-rose.com) is a freelance medical writer based in San Francisco.




This article was provided by San Francisco AIDS Foundation. It is a part of the publication Bulletin of Experimental Treatments for AIDS. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art58349.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.